Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the ‘a’ epitope of the surface antigen are sensitive to ganciclovir
| Autor: | Gek Keow Lim, Nichole Lim, Gek San Tan, Ai Lin Leong, Wei Ning Chen, Chong Jin Oon, Shiuan Koh |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male Hepatitis B virus HBsAg DNA polymerase Hepatitis B virus DNA polymerase Molecular Sequence Data DNA-Directed DNA Polymerase medicine.disease_cause Antiviral Agents Hepatitis B virus PRE beta Epitope Epitopes Virology medicine Humans Amino Acid Sequence Ganciclovir Polymerase Pharmacology Hepatitis B Surface Antigens biology virus diseases Drug Resistance Microbial Hepatitis B biology.organism_classification Molecular biology digestive system diseases Hepadnaviridae Lamivudine DNA Viral Mutation biology.protein Drug Therapy Combination |
| Zdroj: | Antiviral Research. 41:113-118 |
| ISSN: | 0166-3542 |
| Popis: | Lamivudine is a new antiviral agent effective against hepatitis B viral (HBV) infections but can result in virus–drug resistance associated with mutations in the conserved ‘YM552DD’ motif of the HBV DNA polymerase. Due to their overlapping coding regions in the HBV genome, mutations in the DNA polymerase may result in substitutions in the hepatitis B surface antigen (HBsAg), albeit outside the antigenic ‘a’ epitope. Here we report the identification of a novel type of lamivudine-related mutations located in both the polymerase (YM552DD→YI552DD) and the ‘a’ epitope of HBsAg (Gly130→Asp130). The same virus carried a HBsAg Gly145→Arg145 mutation prior to therapy. Both the wild type HBV and lamivudine-related mutants with the Gly145→Arg145 HBsAg mutation were suppressed following ganciclovir treatment, indicating a beneficial additive effect of both drugs against different forms of HBV mutants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect